The severity depends on factors like age, genetics, amount of weight lost, and how quickly it was lost
However, it is not FDA-approved and currently still in evaluation
It has converted them from using the compounded versions to the brand
GHK-Cu Leitfaden: Wirkmechanismus, Dosierung, Haut- und Haarforschung
CJC-1295 + Ipamorelin (Growth Hormone Secretagogues) What they do: Stimulate your body to release growth hormone Marketed claims: Anti-aging Muscle growth Fat loss Better sleep Skin improvement The reality: CJC-1295 has reported serious cardiovascular events (FDA flagged this) Ipamorelin is less studied Growth hormone manipulation has known risks (cancer, organ growth) FDA status: Both banned from compounding WADA status: Prohibited (growth hormone-releasing substances) Common in: Anti-aging clinics, bodybuilding communities 4
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
